271 related articles for article (PubMed ID: 37410242)
21. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
22. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
23. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
24. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
25. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
26. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
Atiq S; Hirshman N; Shariff A; Zhang T
Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
[TBL] [Abstract][Full Text] [Related]
27. Antibody-drug conjugates for the treatment of urothelial carcinoma.
Ravi P; McGregor BA
Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
[TBL] [Abstract][Full Text] [Related]
28. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
[TBL] [Abstract][Full Text] [Related]
29. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
[TBL] [Abstract][Full Text] [Related]
30. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
McGuinness JE; Kalinsky K
Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
[TBL] [Abstract][Full Text] [Related]
31. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
32. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
33. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
34. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
[No Abstract] [Full Text] [Related]
35. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
36. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
[TBL] [Abstract][Full Text] [Related]
38. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
39. A new era in the treatment of urothelial carcinoma.
Faltas B
Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
[TBL] [Abstract][Full Text] [Related]
40. Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
Yamamoto S; Kato M; Matsue T; Yukimatsu N; Takeyama Y; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
Jpn J Clin Oncol; 2024 Feb; 54(2):221-224. PubMed ID: 37886853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]